S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
Log in
OTCMKTS:CTDH

Cyclo Therapeutics Stock Forecast, Price & News

$8.24
-0.13 (-1.55 %)
(As of 03/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.05
Now: $8.24
$8.89
50-Day Range
$0.09
MA: $6.68
$13.33
52-Week Range
$0.03
Now: $8.24
$0.35
Volume200,659 shs
Average Volume245,004 shs
Market Capitalization$1.40 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.89
Cyclo Therapeutics, Inc., a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. It has a collaboration with the Chattanooga Center for Neurologic Research. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in October 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Industrial organic chemicals
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CTDH
CUSIPN/A
Phone386-418-8060
Employees5
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.01 million

Profitability

Net Income$-7,530,000.00
Net Margins-903.35%

Miscellaneous

Market Cap$1.40 billion
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.42 out of 5 stars

Medical Sector

1695th out of 1,968 stocks

Industrial Organic Chemicals Industry

30th out of 38 stocks

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$8.24
-0.13 (-1.55 %)
(As of 03/3/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CTDH News and Ratings via Email

Sign-up to receive the latest news and ratings for CTDH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cyclo Therapeutics (OTCMKTS:CTDH) Frequently Asked Questions

What stocks does MarketBeat like better than Cyclo Therapeutics?

Wall Street analysts have given Cyclo Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cyclo Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has Cyclo Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Cyclo Therapeutics' stock was trading at $0.1155 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CTDH stock has increased by 7,034.2% and is now trading at $8.24.
View which stocks have been most impacted by COVID-19
.

Who are Cyclo Therapeutics' key executives?

Cyclo Therapeutics' management team includes the following people:
  • Mr. N. Scott Fine, Chief Exec. Officer (Age 63, Pay $479.58k)
  • Dr. Jeffrey L. Tate, COO, Chief Quality Officer & Director (Age 62, Pay $252.93k)
  • Dr. Sharon H. Hrynkow, Chief Scientific Officer, Sr. VP of Medical Affairs & Member of Scientific Advisory Board (Age 60, Pay $337.08k)
  • Mr. Joshua M. Fine, CFO & Sec. (Age 38)
  • Mr. George L. Fails, Exec. VP and Operations Mang. (Age 75)
  • Mr. Michael Eric Lisjak, Chief Regulatory Officer & Sr. VP for Bus. Devel.

Who are some of Cyclo Therapeutics' key competitors?

What other stocks do shareholders of Cyclo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclo Therapeutics investors own include Roku (ROKU), Advanced Micro Devices (AMD), Heat Biologics (HTBX), AT&T (T), American Airlines Group (AAL), Aurora Cannabis (ACB), Albemarle (ALB), Yamana Gold (AUY), Alteryx (AYX) and (CGC).

What is Cyclo Therapeutics' stock symbol?

Cyclo Therapeutics trades on the OTCMKTS under the ticker symbol "CTDH."

How do I buy shares of Cyclo Therapeutics?

Shares of CTDH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cyclo Therapeutics' stock price today?

One share of CTDH stock can currently be purchased for approximately $8.24.

How much money does Cyclo Therapeutics make?

Cyclo Therapeutics has a market capitalization of $1.40 billion and generates $1.01 million in revenue each year.

How many employees does Cyclo Therapeutics have?

Cyclo Therapeutics employs 5 workers across the globe.

What is Cyclo Therapeutics' official website?

The official website for Cyclo Therapeutics is www.ctd-holdings.com.

Where are Cyclo Therapeutics' headquarters?

Cyclo Therapeutics is headquartered at 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653.

How can I contact Cyclo Therapeutics?

Cyclo Therapeutics' mailing address is 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653. The biotechnology company can be reached via phone at 386-418-8060 or via email at [email protected]


This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.